European Journal of Pediatrics

, Volume 163, Issue 2, pp 67–75 | Cite as

Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring

  • Antonio Baldellou
  • Generoso Andria
  • Pauline E. Campbell
  • Joel Charrow
  • Ian J. Cohen
  • Gregory A. Grabowski
  • Chris M. Harris
  • Paige Kaplan
  • Kieran McHugh
  • Eugen Mengel
  • Ashok Vellodi
Original Paper

Abstract

In individuals with non-neuronopathic Gaucher disease, childhood manifestations are usually predictive of a more severe phenotype. Although children with Gaucher disease are at risk of irreversible disease complications, early intervention with an optimal dose of enzyme therapy can prevent the development of complications and ensure adequate, potentially normal, development through childhood and adolescence. Very few, if any, children diagnosed by signs and symptoms should go untreated. Evidence suggests that disease severity, disease progression and treatment response in different organs where glucocerebroside accumulates are often non-uniform in affected individuals. Therefore, serial monitoring of the affected compartments is important. This should include a thorough physical examination at 6- to 12-monthly intervals. Neurological assessment should be performed to rule out neurological involvement and should be undertaken periodically thereafter in children who are considered to have risk factors for developing neuronopathic disease. Haematological and biochemical markers, such as haemoglobin, platelet counts and chitotriosidase levels, should be assessed every 3 months initially, but when clinical goals have been met through treatment with enzyme therapy, the frequency can be reduced to every 12 to 24 months. Careful monitoring of bone disease is vitally important, as the resulting sequelae are associated with the greatest level of morbidity. By combining various imaging modalities, the skeletal complications of non-neuronopathic Gaucher disease can be effectively monitored so that irreversible skeletal pathology is avoided and pain due to bone involvement is diminished or eliminated. Monitoring must include regular psychosocial, functional status and quality-of-life evaluation, as well as consistent assessment of therapeutic goal attainment and necessary dosage adjustments based on the patient’s progress. Conclusion: Through comprehensive and serial monitoring, ultimately, a therapeutic dose of enzyme therapy that achieves sustained benefits can be found for each child with non-neuronpathic Gaucher disease.

Keywords

Gaucher disease Management Monitoring Paediatric Quality-of-life 

Abbreviations

ACE

angiotensin-converting enzyme

BMD

bone mineral density

DXA

dual-energy X-ray absorptiometry

QoL

quality-of-life

TRAP

tartrate-resistant acid phosphatase

Notes

Acknowledgements

This publication was supported by an educational grant from Genzyme Corporation.

References

  1. 1.
    Aerts JMFG, Hollak CEM (1997) Plasma and metabolic abnormalities in Gaucher’s disease. Baillière’s Clin Haematol 10: 691–709Google Scholar
  2. 2.
    Allison JW, James CA, Arnold GL, Stine KC, Becton DL, Bell JM (1998) Reconversion of bone marrow in Gaucher disease treated with enzyme therapy documented by MR. Pediatr Radiol 28: 237–240CrossRefPubMedGoogle Scholar
  3. 3.
    Ashkenazi A, Zaizov R, Matoth Y (1986) Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease. Eur J Pediatr 145: 138–141PubMedGoogle Scholar
  4. 4.
    Babyn PS, Ranson M, McCarville ME (1998) Normal bone marrow: signal characteristics and fatty conversion. Magn Reson Imaging Clin N Am 6: 473–495PubMedGoogle Scholar
  5. 5.
    Bamiou DE, Campbell P, Liasis A, Page J, Sirimanna T, Boyd S, Vellodi A, Harris C (2001) Audiometric abnormalities in children with Gaucher disease type 3. Neuropediatrics 32: 136–141CrossRefPubMedGoogle Scholar
  6. 6.
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE (1991) Replacement therapy for inherited enzyme deficiency – macrophage targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324: 1464–1470Google Scholar
  7. 7.
    Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ (2002) Bone complications in children with Gaucher disease. Br J Radiol 75[Suppl 1]: A37–A44Google Scholar
  8. 8.
    Beutler E, Grabowski GA (2001) Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn, vol III. McGraw-Hill, New York, pp 3635–3668Google Scholar
  9. 9.
    Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM, Mannens MM, Aerts JM (1998) The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 273: 25680–25685CrossRefPubMedGoogle Scholar
  10. 10.
    Casal JA, Lacerda L, Perez LF, Pinto RA, Clara Sa Miranda M, Carlos Tutor J (2002) Relationships between serum markers of monocyte/macrophage activation in type 1 Gaucher’s disease. Clin Chem Lab Med 40: 52–55PubMedGoogle Scholar
  11. 11.
    Cassidy L, Taylor D, Harris C (2000) Abnormal supranuclear eye movements in the child: a practical guide to examination and interpretation. Surv Ophthalmol 44: 479–506CrossRefPubMedGoogle Scholar
  12. 12.
    Charrow J, Esplin JA, Gribble TJ, Kaplan P, Kolodny EH, Pastores GM, Scott CR, Wappner RS, Weinreb NJ, Wisch JS (1998) Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158: 1754–1760CrossRefPubMedGoogle Scholar
  13. 13.
    Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A (2000) The Gaucher Registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 2835–2843CrossRefPubMedGoogle Scholar
  14. 14.
    Cohen IJ (2000) Managing Gaucher. Isr Med Assoc J 2: 260PubMedGoogle Scholar
  15. 15.
    Cohen IJ, Zaizov R (1998) Reply to a commentary by Elstein et al. Blood Cells Mol Dis 24: 306–308CrossRefPubMedGoogle Scholar
  16. 16.
    Cohen IJ, Kornreich L, Mekhmandarov S, Katz K, Zaizov R (1996) Effective treatment of painful bone crises in type I Gaucher’s disease with high dose prednisolone. Arch Dis Child 75: 218–222PubMedGoogle Scholar
  17. 17.
    Cohen IJ, Katz K, Kornreich L, Horev G, Frish A, Zaizov R (1998) Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood Cells Mol Dis 24: 296–302CrossRefPubMedGoogle Scholar
  18. 18.
    Damiano AM, Pastores GM, Ware JE Jr (1998) The health-related quality of life of adults with Gaucher’s disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 7: 373–386CrossRefPubMedGoogle Scholar
  19. 19.
    Ek M, Guijt M, Oosterveld P, Hollak CEM (1999) Quality of life in patients with Gaucher disease in the Netherlands (abstract). 3rd Meeting of the European Working Group on Gaucher Disease, Lemnos, GreeceGoogle Scholar
  20. 20.
    Ellis KJ, Shypailo RJ, Hardin DS, Perez MD, Motil KJ, Wong WW, Abrams SA (2001) Z score prediction model for assessment of bone mineral content in pediatric diseases. J Bone Miner Res 16: 1658–1664PubMedGoogle Scholar
  21. 21.
    Erikson A (2001) Remaining problems in the management of patients with Gaucher disease. J Inherit Metab Dis 24[Suppl 2]: 122–126Google Scholar
  22. 22.
    Giraldo P, Pocovi M, Perez-Calvo J, Rubio-Felix D, Giralt M (2000) Report of the Spanish Gaucher’s disease registry: clinical and genetic characteristics. Haematologica 85: 792–799PubMedGoogle Scholar
  23. 23.
    Grabowski GA, Leslie N, Wenstrup R (1998) Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 12: 115–133PubMedGoogle Scholar
  24. 24.
    Grabowski GA, Andria G, Baldellou A, Campbell PE, Cohen IJ, Harris CM, Kaplan P, Mengel E, Pocovi M, Vellodi A (2003) Paediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Eur J Pediatr (in press)Google Scholar
  25. 25.
    Harris CM, Taylor DSI, Vellodi A (1999) Ocular motor abnormalities in Gaucher disease. Neuropediatrics 30: 289–293CrossRefPubMedGoogle Scholar
  26. 26.
    Hayes RP, Grinzald KA, Duffey EB, Elsas LJ II (1998) The impact of Gaucher disease and its treatment on quality of life. Qual Life Res 7: 521–534CrossRefPubMedGoogle Scholar
  27. 27.
    Hermann G, Goldblat J, Levy RN, Goldsmith SJ, Desnick RJ, Grabowski GA (1986) Gaucher’s disease type I: assessment of bone involvement by CT and scintigraphy. AJR Am J Roentol 147: 943–948Google Scholar
  28. 28.
    Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B (2001) The Faces Pain Scale-Revised: toward a common metric in pediatric pain measurement. Pain 93: 173–183CrossRefPubMedGoogle Scholar
  29. 29.
    Hill SC, Damaska BM, Ling A, Patterson K, Di Bisceglie AM, Brady RO, Barton NW (1992) Gaucher disease: abdominal MR imaging findings in 46 patients. Radiology 184: 561–566PubMedGoogle Scholar
  30. 30.
    Hollak CE, Maas M, Aerts JM (2001) Clinically relevant therapeutic endpoints in type 1 Gaucher disease. J Inherit Metab Dis 24[Suppl 2]: 97–105Google Scholar
  31. 31.
    Iuliano-Burns S, Mirwald RL, Bailey DA (2001) Timing and magnitude of peak height velocity and peak tissue velocities for early, average, and late maturing boys and girls. Am J Human Biol 13: 1–8CrossRefPubMedGoogle Scholar
  32. 32.
    Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, Wappner RS, Wisch JS, Weinreb NJ (1996) Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 129: 149–153PubMedGoogle Scholar
  33. 33.
    Kaplan P, Andersson HC, Charrow J, Kolodny EH, Mistry P, Pastores GM, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, for the International Collaborative Gaucher Group (2001) Growth improvement in response to enzyme replacement therapy (ERT) among children with Gaucher disease: the Gaucher Registry (abstract). 51st Annual Meeting of the American Society of Human Genetics, San Diego, CA, October 2001Google Scholar
  34. 34.
    Katz K, Cohen IJ, Ziv N, Grunebaum M, Zaizov R, Yosipovitch Z (1987) Fractures in children who have Gaucher disease. J Bone Joint Surg Am 69: 1361–1370PubMedGoogle Scholar
  35. 35.
    Katz K, Mechlis-Frish S, Cohen IJ, Horev G, Zaizov R, Lubin E (1991) Bone scans in the diagnosis of bone crisis in patients who have Gaucher disease. J Bone Joint Surg Am 73: 513–517PubMedGoogle Scholar
  36. 36.
    Katz K, Sabato S, Horev G, Cohen IJ, Yosipovitch Z (1993) Spinal involvement in children and adolescents with Gaucher disease. Spine 18: 332–335PubMedGoogle Scholar
  37. 37.
    Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, Phillip M, Yaniv Y, Cohen IJ (2000) Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy. Isr Med Assoc J 2: 158–163PubMedGoogle Scholar
  38. 38.
    Kocher MS, Hall JE (2000) Surgical management of spinal involvement in children and adolescents with Gaucher’s disease. J Pediatr Orthop 20: 383–388CrossRefPubMedGoogle Scholar
  39. 39.
    Maas M, Poll LW, Terk MR (2002) Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 75[Suppl 1]: A13–A24Google Scholar
  40. 40.
    Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK (1999) Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 8: 263–268CrossRefPubMedGoogle Scholar
  41. 41.
    Moore SG, Dawson KL (1990) Red and yellow marrow in the femur: age related changes in appearance at MR imaging. Radiology 175: 219–223PubMedGoogle Scholar
  42. 42.
    Pastores GM, Patel MJ, Firooznia H (2000) Bone and joint complications related to Gaucher disease. Curr Rheumatol Rep 2: 175–180PubMedGoogle Scholar
  43. 43.
    Richards SM, Olson TA, McPherson JM (1993) Antibody response in patients with Gaucher disease after repeated infusions with macrophage-targeted glucocerebrosidase. Blood 82: 1402–1405PubMedGoogle Scholar
  44. 44.
    Rite S, Baldellou A, Giraldo P, Labarta JI, Giralt M, Rubio-Felix D, Guallar A, Perez-Calvo JI, Mayayo E, Ferrandez A, Pocovi M (2002) Insulin-like growth factors in childhood-onset Gaucher disease. Pediatr Res 52: 109–112PubMedGoogle Scholar
  45. 45.
    Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, Rosen BR, Baker J, Niklason LT, Hill SC (1995) Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629–635Google Scholar
  46. 46.
    Vellodi A, Bembi B, de Villemeur TB, Collin-Histed T, Erikson A, Mengel E, Rolfs A, Tylki-Szymanska A, Neuronopathic Gaucher Disease Task Force of the European Working Group on Gaucher Disease (2001) Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24: 319–327CrossRefPubMedGoogle Scholar
  47. 47.
    Waitches G, Zawin JK, Poznanski AK (1994) Sequence and rate of bone marrow conversion in the femora of children as seen on MR imaging: are accepted standards accurate? AJR Am J Roentgenol 162: 1399–1406PubMedGoogle Scholar
  48. 48.
    Ware JE, Snow KK, Kosinski M, Gandek B (1976) SF-36 Health Survey Manual and Interpretation Guide. New England Medical Center, The Health Institute, Boston, Massachussets, USAGoogle Scholar
  49. 49.
    Zhao H, Bailey L, Ponce E, Leslie N, Grabowski, GA (2003) Correlations of clinical, chitotriosidase and neutralizing antibody titres during enzyme therapy in Gaucher disease. BCMD 30: 90–96CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Antonio Baldellou
    • 1
  • Generoso Andria
    • 2
  • Pauline E. Campbell
    • 3
  • Joel Charrow
    • 4
  • Ian J. Cohen
    • 5
  • Gregory A. Grabowski
    • 6
  • Chris M. Harris
    • 3
  • Paige Kaplan
    • 7
  • Kieran McHugh
    • 8
  • Eugen Mengel
    • 9
  • Ashok Vellodi
    • 10
  1. 1.Unidad de Enfermedades MetabólicasHospital Infantil Miguel ServetZaragoza Spain
  2. 2.Department of PaediatricsFederico II UniversityNaples Italy
  3. 3.Plymouth Institute of NeurosciencePlymouth and Great Ormond Street Hospital for ChildrenLondon UK
  4. 4.Department of Paediatrics, Feinberg School of MedicineNorthwestern University, and Section of Clinical Genetics, Children’s Memorial HospitalChicago USA
  5. 5.Department of Paediatric Haematology Oncology, Schneider Children’s Medical CentreSackler School of Medicine, Tel Aviv University Israel
  6. 6.Division and Programme in Human GeneticsChildren’s Hospital Research FoundationCincinnati USA
  7. 7.Section of Metabolic DiseasesChildren’s Hospital of Philadelphia and University of PennsylvaniaPhiladelphia USA
  8. 8.Department of RadiologyGreat Ormond Street Hospital for ChildrenLondon UK
  9. 9.Children’s HospitalJohannes-Gutenburg UniversityMainz Germany
  10. 10.Metabolic UnitGreat Ormond Street Hospital for ChildrenLondon UK

Personalised recommendations